Floatz logo

Carboplatin

Squamous Cell Carcinoma

Neonc Technologies, Inc.Small moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Oxford
Phase 3BB
Docetaxel
Hummingbird Bioscience
Phase 2BB
Eloxatin
University of Oxford
Phase 3BB
Fibrin Sealant
Oxford University Hospitals NHS Trust
Phase 4BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →